PaxVax Signs R&D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections

June 10, 2014 PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. …